Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AstraZeneca deal was largest drug merger in Europe, surpassing $28B Novartis combination. Combined $67B market cap made it the world’s third-largest drug firm.
Post-merger R&D productivity declined significantly. Longitudinal study of 2005-2010 pipeline identified systemic attrition issues and proposed…
Astra’s Prilosec patent cliff put $6.2B in global sales at risk. The merger was partly defensive, building scale to weather the coming generic competition…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Astra AB and Zeneca Group plc merged in a ~$35 billion all-share merger of equals to create AstraZeneca, the world's third-largest pharmaceutical company by sales. Zeneca shareholders received 53.5% and Astra shareholders 46.5% of the combined entity. The deal was completed in just 80 days.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astra AB / Zeneca Group plc (this deal) | 1998 | $35.0B | 94 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
← Browse all deals · How we score deals
More: 1998 deals · Cardiovascular deals